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the same promoter, encoding latency-associated nuclear antigen 










































































































































Nutlin-3a activates p53 and its target genes in PEL cells. 
KSHV-infected PEL cells (BC-1, BC-3, and BCBL-1), 
EBV-transformed LCLs (CZE and IHE), and cells with 
mutant p53 (DG-75 and HL-60) were incubated for 12 
hours in the presence (+) or absence (–) of 7 μM Nutlin-3a. 
Whole-cell lysates were subjected to SDS-PAGE fol-
lowed by Western blotting and analyzed for p53, MDM2, 
phosphorylated-p53(Ser15) [p-p53(Ser15)], 53BP1, 
p21CIP1, and Bax expression. Actin immunoblot is shown 
as a loading control.
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Nutlin-3a induces cell-cycle arrest in PEL cells and EBV-transformed LCLs. Asynchronously growing PEL cells (BC-1, BC-3, and BCBL-1; A), 
EBV-transformed LCLs (CZE and IHE; B), and mutant p53 cells (DG-75 and HL-60; C) were treated with 7 μM Nutlin-3a or vehicle control for 
the indicated time periods. Cells were pulse-labeled with BrdU and analyzed for DNA content by flow cytometry. BrdU incorporation during the 
S phase is indicated as percentage of stained cells. The sub-G1 populations in PEL cells are denoted by arrows. Data are representative of 3 
independent experiments.
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Nutlin-3a has cytotoxic activity in PEL cells. (A) 
PEL cell lines (BC-1, BC-3, and BCBL-1) and 
KSHV-infected LCL IHH (green symbols), EBV-
transformed LCLs (CZE and IHE; blue sym-
bols), or mutant p53 cells (DG-75 and HL-60; 
red symbols) were cultured for 5 days with 7 μM 
Nutlin-3a. Cell viability was determined by try-
pan blue exclusion at the indicated time points. 
Results are shown as survival curves denoting 
percentage of viable cells relative to the vehicle 
control. Data represent the mean of 3 indepen-
dent experiments. (B) Scatter plot of annexin V– 
FITC/PI flow cytometry of BC-1 cells after 
exposure to 7 μM of Nutlin-3a or vehicle con-
trol for different time periods. (C) Apoptosis in 
BC-3, BCBL-1, CZE, IHE, DG-75, and HL-60 
cells was assessed at 96 hours after treat-
ment with 7 μM Nutlin-3a or vehicle control by 
annexin V–FITC/PI binding and measured by 
flow cytometry analysis. Lower left quadrants 
represent viable cells (annexin V– and PI-neg-
ative); lower right quadrants represent early 
apoptotic cells (annexin V–positive, PI-nega-
tive) demonstrating cytoplasmic membrane 
integrity; upper right quadrants represent non-
viable, late apoptotic cells (annexin V– and PI-
positive). Numbers indicate the percentage of 
cells in each quadrant. Shown is 1 representa-
tive experiment of 3.
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Disruption of the p53-MDM2-LANA complex triggers the cytotoxic 
effect of Nutlin-3a in KSHV lymphomas. Nutlins were designed to 
inhibit interaction of MDM2 with p53 and to disrupt complex 
formation between the 2 proteins (15). Consequentially, they 



















Nutlin-3a selectively kills KSHV-infected cells. (A) U2OS and EA.hy 926 cells in the absence 
or presence of latent rKSHV infection were treated with 7 μM Nutlin-3a, and cell death was 
assessed by trypan blue exclusion at 24, 48, and 96 hours of treatment. Values represent the 
percentage of dead cells induced by Nutlin-3a treatment. The percentage of dead cells in the 
DMSO control was subtracted as a background. Each value represents the mean of 3 inde-
pendent experiments. (B) Noninfected and rKSHV-infected EA.hy 926 cells were incubated for 
12 hours in the presence or absence of 7 μM Nutlin-3a. Whole-cell lysates were subjected to 
SDS-PAGE followed by Western blotting and analyzed for p53 and MDM2 expression. Actin 
immunoblot is shown as a loading control.
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Nutlin-3a is a potent agent for treating KSHV lymphomas in vivo. 
























DNA damage signaling enhances the cytotoxic effect of Nutlin 3a. (A) BC-3 and CZE cells were immunostained with antibody against γH2AX, the 
phosphorylated form of histone H2AX. The nuclear morphology was visualized by Hoechst staining. (B) Percentage of γH2AX-positive cells in 
PEL cells (BC-1, BC-3, and BCBL-1) and EBV-transformed LCLs (CZE and IHE). Results represent the mean of 2 independent experiments. (C) 
BC-1, BC-3, BCBL-1, CZE, IHE, DG-75, and HL-60 cells were incubated for 12 hours in the presence or absence of 7 μM Nutlin-3a. Whole-cell 
lysates were subjected to SDS-PAGE followed by Western blotting and analyzed for phosphorylated Chk2(Thr68) and total Chk2 expression. 
(D) Survival curves for BC-1, IHH, and IHE cells (some gamma-irradiated at 1 Gy; IR) incubated with Nutlin-3a in the presence or absence of 
caffeine (2 mM). Cell death was determined by trypan blue exclusion at 24, 48, and 72 hours after treatment. Values represent the percentage 
of viable cells relative to that of DMSO control.
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Nutlin-3a disrupts the p53-MDM2-LANA interaction. (A) Extracts from the BC-3 cell line 
exposed for 12 hours to vehicle control or 7 μM Nutlin-3a were separated using gel filtration 
chromatography. Fractions were analyzed by Western blotting with antibodies against p53, 
MDM2, and LANA. The elution profile of molecular weight standards is indicated above the 
lanes. (B) The peak fractions for LANA (asterisks in A) from BC-3 cells treated with either 
vehicle control or 7 μM Nutlin-3a for 12 hours were used in immunoprecipitations with anti-
p53 or anti-MDM2 antibodies. As a control, a duplicate sample from the same fraction was 
immunoprecipitated with mouse IgG. Immunocomplexes were resolved by SDS-PAGE and 
analyzed by Western blotting with antibodies against p53, MDM2, and LANA.
Figure 7
Antitumor activity of Nutlin-3a in vivo. Growth curves of Nutlin-3a– and 
vehicle control–treated BC-3 tumors. Balb/c nude mice were injected 
subcutaneously with 6 × 106 BC-3 cells. When the tumors had grown to 
palpable size, the mice were treated intraperitoneally with the vehicle 
control (filled squares) or 20 mg/kg of Nutlin-3a (open circles). Nutlin-3a 
treatment resulted in regression of tumors; at the end of treatment, 
these tumors were significantly smaller than those treated with vehicle 
(P = 0.02). Dashed line indicates the volume of Matrigel in the tumor. 
Data (mean and SEM) are representative of 2 independent experi-
ments. Inset shows a photograph of BC-3 tumor–bearing Balb/c nude 
mice treated with either vehicle control or 20 mg/kg Nutlin-3a 7 times 
over the course of 2 weeks.
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